login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
COYA THERAPEUTICS INC (COYA) Stock News
NASDAQ:COYA -
US22407B1089
-
Common Stock
6.56
USD
-0.17 (-2.53%)
Last: 8/27/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
COYA Latest News, Press Relases and Analysis
All
Press Releases
19 hours ago - By: Zacks Investment Research
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
3 days ago - By: Benzinga
- Mentions:
BFLY
EPIX
CSCI
MOLN
...
12 Health Care Stocks Moving In Monday's After-Market Session
3 days ago - By: Benzinga
What's Going On With Coya Therapeutics Stock?
16 days ago - By: Zacks Investment Research
- Mentions:
CVAC
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
AUNA
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
16 days ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
21 days ago - By: Zacks Investment Research
- Mentions:
RGNX
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
22 days ago - By: Zacks Investment Research
- Mentions:
EYPT
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
a month ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
a month ago - By: Coya Therapeutics, Inc.
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
2 months ago - By: ACCESS Newswire
- Mentions:
INUV
DGXX
DGX.CA
SURG
...
Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
2 months ago - By: ACCESS Newswire
- Mentions:
INUV
DGXX
DGX.CA
SURG
...
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
2 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
3 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
3 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
4 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
4 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
4 months ago - By: Zacks Investment Research
- Mentions:
DOCS
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
4 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
4 months ago - By: Zacks Investment Research
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
4 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
4 months ago - By: Atea Pharmaceuticals, Inc.
- Mentions:
AVIR
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
5 months ago - By: Yahoo Finance
- Mentions:
KC
HTGC
CNC
AVDX
...
Why Kingsoft Cloud Holdings Limited (KC) Surged On Friday?
5 months ago - By: Yahoo Finance
- Mentions:
GLPG
GLRE
CNC
GANX
...
Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
5 months ago - By: Yahoo Finance
- Mentions:
GLRE
KC
GANX
LOAR
...
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
5 months ago - By: Yahoo Finance
- Mentions:
GANX
GLRE
CNC
EGY
...
Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
5 months ago - By: Yahoo Finance
- Mentions:
NAT
GES
XOM
ACMR
...
Nordic American Tankers Limited (NAT): One of the High-Dividend Stocks to Invest In Under $10
5 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
5 months ago - By: Zacks Investment Research
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
5 months ago - By: Zacks Investment Research
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet
5 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
5 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
6 months ago - By: Coya Therapeutics, Inc.
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
Please enable JavaScript to continue using this application.